Abstract:Understanding the mechanisms that give rise to neurodegenerative diseases, in particular Alzheimer's disease, is of fundamental importance for the development of mechanism-based therapies. Alzheimer's disease is defined by the development of extracellular deposits of beta-amyloid and intraneuronal tau inclusions. Of these, tau inclusions correlate better with the loss of cognitive function. Moreover, tau inclusions are also found in a large number of other neurodegenerative diseases, including progressive supranuclear palsy, chronic traumatic encephalopathy and Pick's disease. Of the protein assemblies characteristic of human neurodegenerative diseases, those made of tau are the most common. Tau aggregates appear to spread through the brain via interconnected nerve cells, giving rise to the concept that they do so through prion-like mechanisms. In experimental systems, such as tauopathy mouse models, the spreading of tau pathology can be recapitulated following the injection of sonicated tau seeds. However, at present it is not possible to validate the prion-like spreading hypothesis from these experiments and extrapolate to the human brain. In order to address this fundamental question, we have quantified tau amplification at the molecular level by studying the evolution of single tau aggregates in vitro over extended times and fitted this data to obtain the rate constants for fibril elongation and fragmentation . We have then developed a simple model to estimate the rate of spreading through an animal or human brain based on these rate constants. We show that the spreading efficiency of tau aggregates depends on their elongation and fragmentation rates, as well as the availability of free cytosolic tau. Importantly, our spreading model is able to recapitulate spreading times in vivo and provides, for the first time, a quantitative framework for analysing the results from animal experiments and for linking them to the development of neuropathological changes in human brain. The prion-like propagation of tau occurs by elongation and fragmentation allowing a simple model to predict the spreading rate of tau assemblies in both animal models and humans. This model shows that inhibiting the rate of tau propagation would be an effective therapeutic strategy.

The Yeast Protein Ure2p Triggers Tau Pathology in a Mouse Model of Tauopathy.

Dysfunction of microtubule-associated proteins of MAP2/tau family in Prion disease.

Dysfunction of Microtubule-Associated Proteins of MAP2/tau Family in Prion Disease

Trans‐seeding of Alzheimer‐related tau protein by a yeast prion

The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson's disease

Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-like Tauopathy.

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Unique Pathological Tau Conformers from Alzheimer'S Brains Transmit Tau Pathology in Nontransgenic Mice

Distinct Microscopic Mechanisms for the Accelerated Aggregation of Pathogenic Tau Mutants Revealed by Kinetic Analysis.

O3‐01‐05: in vitro measurements of tau aggregate elongation and fragmentation rates allow the modelling of prion‐like spreading in humans

Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease

PM2.5 triggers tau aggregation in a mouse model of tauopathy

Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles*

Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys

Α-Synuclein Modulates Tau Spreading in Mouse Brains

Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease

Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Tau mutation S356T in the three repeat isoform leads to microtubule dysfunction and promotes prion-like seeded aggregation

Amyloid-β Plaques Enhance Alzheimer's Brain Tau-Seeded Pathologies by Facilitating Neuritic Plaque Tau Aggregation